Immunomedics announced the availability of Trodelvy™ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at ...

Gilead Sciences, Inc. (GILD) announced on Monday that its late-stage study showed a combination of its drug Trodelvy with Merck's (MRK) immuno-oncology agent Keytruda significantly improved ...

FOSTER CITY, Calif., May 31, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease ...

Withhold Trodelvy for absolute neutrophil count below 1500/mm3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Consider G-CSF for secondary prophylaxis.

The results of Gilead's much-anticipated TROPiCS-02 study of Trodelvy are in, and while the company says top-line data are positive, its guarded stance has rung some alarm bells. In the study ...

Gilead Sciences, Inc. is presenting new data from the Phase 3 ASCENT trial of Trodelvy ® in metastatic triple-negative breast cancer at the 2020 San Antonio Breast Cancer Symposium being held ...

Gilead Sciences Inc's Trodelvy extended by 3.2 months the survival of patients with advanced stages of a common type of breast cancer, according to data released ahead of a presentation at a ...

Gilead has made the decision to withdraw the accelerated approval of Trodelvy ® (sacituzumab govitecan-hziy) for metastatic urothelial cancer in the US. Trodelvy, a Trop-2-directed antibody and ...

In the space of a couple of months, Gilead Sciences' Trodelvy impact on overall survival (OS) in the TROPICs-02 trial in advanced breast cancer has gone from a trend to a statistically significant ...